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0.8%), TVR (3.9 vs 2.8%), death (2.2 vs 2.8%), and MACE (6.1 vs 5.7%) as those with- 
out prior angina (P=NS for all). Further, during 1-year follow-up, no difference was found 
in the incidence of death (4.7 vs 5.6%, p=0.60) or MACE (23 vs 17%, p=0.07), between 
patients with and those without prior angina. 
Conclusions: A history of angina prior to acute myocardial infarction does not confer 
protection from adverse outcomes in patients undergoing primary angioplasty. Our find- 
ings challenge the clinical relevance of ischamic pre-conditioning in such patients. 
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1101-33 Characteristics and Outcome of Patients With ST 
Elevation Versus Non-ST Elevation Myocardial 
Infarction: Results of the MONICA Augsburg Myocardial 
Infarction Registry 1985-1995 
Bernhard Kuch, Heinz D. Bolte, Wolfgang von Scheidt, Hannelore L5wal, L Medizinische 
Klinik, Klinikum Augsburg, Augsburg, Germany, GSF-Forschungsinstitut, Neuherherg, 
Germany. 
Background: The classification of myocardial infarction (MI) has been more and more 
moved from discerning Q-wave from Non-Q-wave MI to classifying MI by ST- wave 
dynamics. Data about patient (pat.) characteristics and prognosis in relation to their ST- 
wave dynamics are scarce. Methods and Results: We, therefore, analyzed ECG-data 
(Minnesota-Coding) from the MONICA Augsburg Myocardial Infarction-Registry from 
1985-1995 (n= 2896; aged 25-75 years; 74% men). ST-Elevation MI (ST-E) was most 
frequent (59%), followed by MI with unspecific ST-changes (neither elevation or depres- 
sion; ST-U; 25%) and MI with ST-depression (ST-D; 16%). Pat. with ST-D were more 
often diabetics than pat. with ST-E or ST-U (28.1 vs. 21.9 and 20.5%; respectively), ware 
more often female (31.5 vs. 26.3 and 19.7%), had more often a history of angina (47.3 
vs. 36.7 and 40.0%) and previous MI (27.6 vs. 19.5 and 23.9%), and were less often 
treated by thrombolytics (13.6 vs. 38.8 and 12.4%; p for all comparisons < 0.001). In 
addition, pat. with ST-D were significantly older, had a higher mean pulse rate during 
admission, and a lower peak CK level than pat. with ST-E (p <0.01 respectively). The 28- 
day-case fatality-rate was 13.2% for ST-D, 10.8% for ST-E, and 7.5% for ST-U, respec- 
tivety (significance only for ST-E vs. ST-U; p < 0.001; for ST-E vs. ST-D p > 1). These 
case-fatality differences were not altered substantially by multivariate testing in a logistic 
regression model including the above mentioned ifferences in history and therapy. 
Conclusion: 25% of MI-pat. had a non-diagnostic ECG. This group has the lowest mortal- 
ity. Despite significant differences in presentation and cardiovascular isk-factor history, 
pat. with ST-elevation did not differ in terms of short-term prognosis from pat. with ST- 
depression. 
1101-34 Opportunities for Enhancing the Use of Evidence-Based 
Medicines for Acute Coronary Syndromes: Insights 
From the SYMPHONY Studies 
Judith Kramer. L. Kristin Newby, John Simes, Frans Van de Weft, Christopher Granger, 
Kerry Lee, Manjushri Bhapkar, Robert Califf, Paul W. Armstrong, University of Alberta, 
Edmonton, Alberta, Canada, Duke Clinical Research Institute, Durham, North Carolina. 
The extent to which evidence-basad therapy [Class IA or IB evidence (AHNACC 9/2000 
and ESC 9/2000)] is applied internationally to the broad cross-section of patients early 
after acute coronary syndromes (ACS) is unknown. Accordingly, we evaluated this issue 
in 15,904 patients from 36 countries entered into the Symphony and 2nd Symphony 
studies of sibrafiban between Aug 1997 and Aug 1999. We analyzed by geographic 
region the use of concomitant medications between each patient's qualifying ACS event 
and start of study treatment [median 91 hrs); and to what extent international variations 
in treatment could be explained by differences in patient risk profile. The data are shown 
in the Table. 
There were important variations in evidence-based treatment of ACS across geographic 
region, which remained highly significant (p<0.001) after adjustment for all major patient 
risk factors for future coronary events. Given the greater use of some treatments but 
lesser use of others within the same region, we believe these findings are unlikely to be 
driven by cost alone. Our data also indicate substantial global opportunities for improving 
secondary prevention. Hence continued monitoring of these international patterns of care 
and development of appropriate interventions to increase adherence to evidence-based 
~]uidelines i a desirable next step. 
Med Class Asia L.Amedca E.Europe W.Europe USA Canada Au/NZ 
n=551 n=557 n=2661 n=3431 n=7185 n=871 n=648 
ASA 87% 86% 75% 82% 85% 88% 91% 
Beta blockers 68% 75% 70% 69% 73% 78% 75% 
Lipid lowering 37% 17% 10% 30% 40% 29% 42% 
ACE inhibitors 56% 50% 48% 30% 33% 36% 33% 
Heparin 37% 61% 55% 52% 78% 79% 51% 
LMWH 27% 16% 28% 34% 10% 11% 34% 
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1101-35 Early Use of Glycoprotein 2b3a Inhibitors and 
Outcomes in Non-ST Elevation Mh Observations From 
the NRMI-4 
Eric D, Peterson, John G. Canto, Charles V. Pollack, Lori Parsons, Matt T. Roe, Kathee 
Littrell, Nathan R. Every, Hal V. Barron, for the NRMI-4 Investigators, Duke C/inica/ 
Research Institute, Durham, North Carolina. 
Background: The recent AHA/ACC ACS Guidelines recommend early use of glycopro- 
tein lib-Ilia inhibitors (GP 2b3a) in non-ST elevation MI (NSTEMI) patients, yet commu- 
nity adoption has been slow. 
Methods: We examined the relationship between "eady use" of GP 2b3a within 24hrs of 
admission and in-hospital mortality in 32,710 NSTEMI patients eligible for GP 263a, 
treated at 1,087 hospitals in the NRMI 4 Registry between July 2000-April 2001. 
Results: Overall, 24% of eligible NSTEMI patients were begun on a GP 2b3a in <24hrs. 
Patients treated with GP 2b3a <24 hrs were younger, more likely male, and had chest 
pain and ST depression on presentation than those not. Unadjusted in-hospital mortality 
rate was significantly lower in those treated with GP 2b3a <24hrs than those not treated 
early (3.2% vs 8.5%, p<0.0001). After adjusting for 13 patient risk factors (NRMI NSTEMI 
risk model, C-index 0.75), and for hospital size, region, teaching affiliation and cath facili- 
ties, patients getting GP 2b3a <24 hrs had 32% lower relative risk for in-hospital mortality 
(adjusted OR 0.68, 95% CI 0.59-0.79). Adjustment for treatment propensity (to receive 
GP 2b3a<24 hrs) revealed similar results. The Figure displays mortality rates by GP2b3a 
use <24hrs according to NRMI risk group. 
Conclusion: Early use of GP 2b3a within 24 hrs of admission was associated with lower 
in-hospital mortality across the NSTEMI risk spectrum. As only 24% of eligible patients 
received early GP2b3a therapy, there is considerable room for quality improvement. 
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1101-36 Comparison of Characteristics, Treatment, and 
Outcomes of Patients Enrolled Versus Not Enrolled in a 
Clinical Trial: Findings From TIMI 9 Registry and 9B 
Trial 
Maria Cecilia Bahit, Elliott M. Antman, Sabina A. Murphy, Carolyn H. McCabe, 
Christopher P. Cannon, Brigham and Women's Hospital, Boston, Massachusetts. 
Background: Because mortality in clinical trials (CT) is generally lower than in registries 
of clinical practice, it has been suspected that patients are lower risk. However, little is 
known about the characteristics of patients included vs. not in CT. Methods: To address 
this issue, TIMI 9 Registry prospectively evaluated characteristics and in-hospital out- 
comes for ST-elevation MI patients at 20 hospitals during the conduct of TIMI 9B trial.We 
compared characteristics, treatment and outcomes of patients in TIMI 9B trial (N=3002), 
with others eligible for thrombotysis but not enrolled in the TIMI 9B thai (N=296), and with 
those not-eligible for thrombolysis by ACC/AHA criteria at the same centers (N=282). 
Results: At TIMI 9 Registry hospitals, 46% of eligible patients were enrolled in TIMI 9B. 
Across the three groups, a gradient of both high-risk baseline characteristics, use of rep- 
effusion therapy and mortality was observed. In addition, although we did not assess 
contraindications for each medication, use of aspirin, (and beta-blockers, ACE inhibitors) 
both initially and at discharge was lower among eligible/not enrolled patients (p<0.0001 
for aspirin) or ineligible patients.(Tabla) 
Conclualon: In this prospective registry, we found that half of eligible patients were 
enrolled. Those not enrolled had higher risk characteristics and worse outcomes; how- 
ever, they also were treated less frequently with guideline-recommended medications, 
which may have contributed to their hi~lher mortality. 
Eligible/ Eligible/not Not eligible/ 3-way p 
enrolled enrolled not enrolled 
Age (years) 60.1 ± 11.9 62.3 ± 13.5 67.5 ± 12.6 <0.0001 
Female gender 25.1% 32.4% 39.5% <0.0001 
Aspirin 99.4% 91.5% 75.2% <0.0001 
Thrombolysis 99.6% 59.8% 22.5% <0.0001 
Primary PCI 0 12.5% 12.7% <0.0001 
In hospital death 5.1% 8.4% 19.8% <0.0001 
Death + MI+ Shock+ severe CHF 9.0% 15.9% 30.1% <0.0001 
1101-37 Approach After Thrombolytic Therapy: Invasive Versus 
Conservative Management: Global Registry of Acute 
Coronary Events 
Immad Sadiq, Harold L Dauerman, Robert J. Goldberg, Warner Klein, David Briagsr, Ph. 
Gabriel Steg, Gilles Montalescot, Josd L6pez-Send6n, Andrzej Budaj, Joel M. Gore, for 
the GRACE Investigators, Saint Vincent Hospital & University of Massachusetts Medical 
School, Worcester, Massachusetts, Medizinische Universitdtsklinik, Graz, Austria. 
Background: Thrombolytics (lyrics) reduce mortality of patients (pts) with acute ST seg- 
ment elevation MI (STE MI). However, the impact of a subsequent invasive strategy on 
outcomes has not been studied in an international population-based setting. 
Methods: 1,766 pts enrolled in GRACE with STE MI who received lytics were divided into 
